| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| Other Sizes |
|
Purity: ≥98%
Verapamil (sold under various trade names such as: Calan, Cordilox, Dexverapamil, Falicard, Finoptin, Hydrochloride, Verapamil, Iproveratril, Isoptin, Isoptine, Izoptin, Lekoptin) is a selective and potent L-type calcium channel blocker in the phenylalkylamine class, it is an FDA approved medication used for the treatment of high blood pressure, angina (chest pain from not enough blood flow to the heart), and supraventricular tachycardia. It may also be used for the prevention of migraines and cluster headaches. It is given by mouth or by injection into a vein.. Verapamil hydrochloride blocks the L-type Ca2+ channels in smooth and cardiac muscle cells. Verapamil is an antiarrhythmic agent and vasodilator known to reduce the renal clearance of digoxin and induce apoptosis in primary and metastatic colon adenocarcinoma human cell lines in vitro. It has been observed that verapamil can induce currents by itself, presumably by acting on the potassium and chloride leakage.
| ln Vitro |
Citric medicines limit the uptake of EverFluor FL Verapamil (EFV) by TR-iBRB2 cells, while verapamil inhibits the uptake in a concentration-dependent manner with an IC50 of 98.0 μM[4].
|
||
|---|---|---|---|
| ln Vivo |
Verapamil, when taken orally, can help control the atrioventricular nodal response in atrial fibrillation and prevent atrioventricular reentry tachycardia[2]. IV verapamil injections are given into femoral veins before ischemia occurs. The incidence of ventricular arrhythmias, such as ventricular tachycardia (VT), ventricular fibrillation (VF), and premature ventricular contractions (PVC), is significantly reduced by verapamil (1 mg/kg) for 45-minute coronary artery occlusion. When the heart experiences ischemia, the total arrhythmia score rises noticeably. The enhancement of total arrhythmia scores brought on by ischemia is significantly inhibited by verapamil (1 mg/kg)[5].
|
||
| Animal Protocol |
|
||
| References |
[1]. Gowarty JL, et al. Verapamil as a culprit of palbociclib toxicity. J Oncol Pharm Pract. 2019 Apr;25(3):743-746.
[2]. Krikler DM. Verapamil in arrhythmia. Br J Clin Pharmacol. 1986;21 Suppl 2:183S-189S. [3]. Zhou P, et al. Anti-arrhythmic effect of Verapamil is accompanied by preservation of cx43 protein in rat heart. PLoS One. 2013 Aug 12;8(8):e71567. [4]. Rehnqvist N,et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J. 1996 Jan;17(1):76-81. [5]. Kubo Y, et al. Blood-to-Retina Transport of Fluorescence-Labeled Verapamil at the Blood-Retinal Barrier. Pharm Res. 2018 Mar 12;35(5):93 |
| Molecular Formula |
C27H38N2O4.HCL
|
|
|---|---|---|
| Molecular Weight |
491.06
|
|
| CAS # |
152-11-4
|
|
| Related CAS # |
Verapamil;52-53-9;Verapamil-d3 hydrochloride;Verapamil-d6 hydrochloride;1185032-80-7;Verapamil-d3-1 hydrochloride;2714485-49-9
|
|
| SMILES |
Cl[H].O(C([H])([H])[H])C1=C(C([H])=C([H])C(=C1[H])C(C#N)(C([H])([H])C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])C1C([H])=C([H])C(=C(C=1[H])OC([H])([H])[H])OC([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])[H])OC([H])([H])[H]
|
|
| InChi Key |
DOQPXTMNIUCOSY-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C27H38N2O4.ClH/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6;/h9-12,17-18,20H,8,13-16H2,1-7H3;1H
|
|
| Chemical Name |
2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile hydrochloride
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0364 mL | 10.1821 mL | 20.3641 mL | |
| 5 mM | 0.4073 mL | 2.0364 mL | 4.0728 mL | |
| 10 mM | 0.2036 mL | 1.0182 mL | 2.0364 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00983242 | Completed Has Results | Drug: Colchicine Drug: Verapamil HCl ER |
Pharmacokinetics | Mutual Pharmaceutical Company, Inc. | September 2008 | Phase 1 |
| NCT04545151 | Recruiting | Drug: Verapamil SR 120 mg Drug: Placebo |
Diabetes Mellitus, Type 1 | Medical University of Graz | February 8, 2021 | Phase 2 |
| NCT02209155 | Terminated | Drug: R-verapamil 75 mg tablet Drug: Placebo |
Episodic Cluster Headache | Center Laboratories, Inc. | November 2013 | Phase 2 |
| NCT00133692 | Completed | Drug: Verapamil SR/Trandolapril /Hydrochlorothiazide (HCTZ) |
Hypertension Coronary Artery Disease |
University of Florida | September 1997 | Phase 4 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA